You are here: Industry Insights > AXS-05

News List

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder drugs
August 25, 2021
Axsome Therapeutics,today announced that the U.S. Food and Drug Administration (FDA) informed the Company in a teleconference on August 20, 2021, that its review of the new drug application (NDA) for AXS-05 for the treatment of major depressive disorder .
Novel pipeline agents to drive global major depressive disorder market: GlobalData expresspharma
April 08, 2021
The major depressive disorder (MDD) market is expected to grow from $3.97 billion in 2019 to $7.87 billion by 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 7.1 per cent, according to GlobalData.
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder pharmafocusasia
March 28, 2019
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therap